AIDS Therapies

International Hydroxyurea Study Use Supported in Triple Combination Therapy

Published in AIDS Weekly, July 27th, 1998

Hydroxyurea, when administered as part of a "protease-sparing" triple combination with the nucleoside analogue drugs ddI (didanosine, Videx) and d4T (stavudine, Zerit), produces significant reductions in HIV viral load compared to the two-drug combination of ddI and hydroxyurea.

The international study conducted in Argentina, Brazil and Canada, is the largest, controlled, hydroxyurea-based trial ever conducted and could provide an important treatment option to patients worldwide that should be further explored. These findings were reported at the 12th International AIDS Conference, held in Geneva, Switzerland, June 28 - July 3, 1998.

"Close to 80...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1998-07-27)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry